CN106279134A — 卡格列净单晶及其制备方法和用途
Assigned to Waterstone Pharmaceuticals Wuhan Co Ltd · Expires 2017-01-04 · 9y expired
What this patent protects
本发明涉及一种卡格列净单晶及其制备方法和用途,述卡格列净单晶的X射线粉末衍射在衍射角2θ=7.95,10.92,13.94,15.46,15.94,18.82,20.27,22.72和26.78度处有特征峰,所得单晶未见报道,测定其晶体结构属斜方晶系,空间群为P2(1)2(1)2(1),晶包内分子数Z=4,常温下为无色针状结晶,形态良好,纯度高达99%;其制备方法使得卡格列净与其他杂质实现良好的分离,且重现性好。
USPTO Abstract
本发明涉及一种卡格列净单晶及其制备方法和用途,述卡格列净单晶的X射线粉末衍射在衍射角2θ=7.95,10.92,13.94,15.46,15.94,18.82,20.27,22.72和26.78度处有特征峰,所得单晶未见报道,测定其晶体结构属斜方晶系,空间群为P2(1)2(1)2(1),晶包内分子数Z=4,常温下为无色针状结晶,形态良好,纯度高达99%;其制备方法使得卡格列净与其他杂质实现良好的分离,且重现性好。
Drugs covered by this patent
- Invokana (CANAGLIFLOZIN) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.